Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meclofenoxate, also known as centrophenoxine, is a cholinergic nootropic compound used both as a dietary supplement and as a drug in some countries. It is an ester formed from dimethylaminoethanol (DMAE) and 4-chlorophenoxyacetic acid. Meclofenoxate acts primarily by increasing the availability of choline in the brain, which enhances acetylcholine synthesis—a neurotransmitter critical for memory and cognitive function. It has been studied for its potential to improve cognitive symptoms associated with dementia and age-related cognitive decline, with some evidence suggesting benefits in memory enhancement and neuroprotection. Meclofenoxate may also increase cellular membrane phospholipids and reduce age-associated lipofuscin accumulation in neural tissue. While it is available over-the-counter or by prescription depending on the country, clinical evidence supporting its efficacy remains limited[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meclofenoxate.